Month: November 2023

Access-to-anti-obesity-medications-for-Black-Americans;-Thanksgiving-and-the-weight-loss-conversation;-a-four-monthly-GLP-1-shot

Access to anti-obesity medications for Black Americans; Thanksgiving and the weight loss conversation; a four-monthly GLP-1 shot.

November 26, 2023 No Comments

AT A GLANCE Atiya Jordan recounts in Black Enterprise the disparity ‘…between the use of the anti-obesity and diabetes medication among Black people…’ while ‘…white people are four times more likely to receive a prescription.’ A new Tema Cardiovascular & Metabolic ETF, or exchange traded fund, seeks to invest ‘…in companies tackling diabetes, obesity and cardiovascular diseases…’ from Bansari Mayur Kamdar at Reuters. Alex Janin writes in

Read More »
Britain & Belgium ban Ozempic for Weight Loss ; AMA urges all Payers to Cover Obesity Medications; An Incredible Transformation in Obesity Care; and Being Overweight is the New Normal in America.

Britain & Belgium ban Ozempic for Weight Loss ; AMA urges all Payers to Cover Obesity Medications; An Incredible Transformation in Obesity Care; and Being Overweight is the New Normal in America.

November 19, 2023 No Comments

AT A GLANCE From Reuters, reporting on Novo Nordisk’s Ozempic, ‘…Britain and Belgium have temporarily banned its use for weight loss to secure availability for diabetics.’ The American Medical Association said it will ‘…urge all payers to ensure coverage parity for evidence-based treatment of obesity, including FDA-approved medications without exclusions or additional carve-outs…’ from STAT. Martin Lange, Novo Nordisk executive vice president of development has ‘…a clear vision of

Read More »
WOW – what a week! FDA approval for Eli Lilly’s tirzetapide drug, Zepbound; Wegovy cuts cardiovascular deaths by 20%; GLP-1s alone will not solve the obesity crisis; 1/3 less walking activity.

WOW – what a week! FDA approval for Eli Lilly’s tirzetapide drug, Zepbound; Wegovy cuts cardiovascular deaths by 20%; GLP-1s alone will not solve the obesity crisis; 1/3 less walking activity.

November 12, 2023 No Comments

AT A GLANCE Elaine Chen and Damian Garde at STAT announce the long-awaited approval of Eli Lilly drug tirzetapide, marketed under the name Zepbound, for obesity. Britney Nguyen at Forbes writes Zepbound ‘…could eventually be the best-selling drug of all time…’ in reference to its recent FDA approval. Pharmaphorum reports on the race to deliver GLP-1 medications to millions who want them. Novo Nordisk is leaving nothing to chance ‘…announcing

Read More »
Calibrate’s rapid downsizing; counterfeit semaglutide in Belgium; Novo and Eli earnings; bariatric surgery for teens; India’s obesity time bomb; and Ozempic as the Taylor Swift of the stock market!

Calibrate’s rapid downsizing; counterfeit semaglutide in Belgium; Novo and Eli earnings; bariatric surgery for teens; India’s obesity time bomb; and Ozempic as the Taylor Swift of the stock market!

November 5, 2023 No Comments

AT A GLANCE Past CEO Isabelle Kenyon writes at Medium on her new role at Calibrate as she hands over the reins to Ed Cudahy and Scott Honken. Belgium’s Federal Agency for Medicines and Health Products told Reuters ‘… it had seized counterfeit versions of semaglutide… in which the injector pens contained insulin….’ as per Patrick Wingrove. This Thursday, ‘…Novo Nordisk and Eli Lilly reported booming sales…’ in

Read More »
Categories
Archives
Scroll to Top
Skip to content